On Monday, the FDA removed the clinical hold on Novavax Inc.’s (NASDAQ:NVAX) Investigational New Drug (IND) application for ...
The FDA agreed for Novavax to continue trials of its vaccine combo after addressing a serious adverse event that paused ...
The FDA had put a clinical hold on Novavax’s COVID-19-influenza combo vaccine after an adverse event in a patient. The U.S.
Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...
The FDA has lifted its clinical hold on Novavax's combined COVID-19 and influenza vaccine trial, finding no link between the ...
After an investigation, the agency concluded that a case of muscle weakness in one of Novavax’s trials was actually ALS and ...
The US Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug (IND) application for ...
The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its ...
Gaithersburg: Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M adjuvant, has announced that ...
Novavax can move forward with a trial for its combined Covid-19 and influenza ... the combination vaccine. Novavax said that it provided additional information to the FDA, leading to the ...
Novavax (NVAX) announced that the U.S. FDA has removed the clinical hold on Novavax’s Investigational New Drug application for its ...
(RTTNews) - Novavax, Inc. (NVAX) Monday said the Food and Drug Administration or FDA has removed the clinical hold on its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine ...